Abstract | BACKGROUND: Reduced-intensity conditioning (RIC) regimens with low tolerable toxicities have been used for allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the relapse rate by this treatment is high. Treatment of CD19 B-cell relapsed/refractory acute lymphoblastic leukemia (r/r ALL) with allogeneic chimeric antigen receptor-modified T (CAR-T) cells is safe and effective. Use of allogeneic CD19-CAR-T cells as a part of RIC regimens for treatment of r/r ALL patients with haploidentical HSCT has not been investigated yet. CASE PRESENTATION: CONCLUSIONS: Treatment of r/r ALL with RIC including CD19-CAR-T cells followed by allo-HSCT was safe and effective, which suggest that CAR-T cells can be used as a part of RIC regimens in the treatment of r/r ALL in haploidentical HSCT.
|
Authors | Cheng Zhang, Pei-Yan Kong, Shiqi Li, Ting Chen, Xun Ni, Yunyan Li, Meiling Wang, Yao Liu, Lei Gao, Li Gao, Xian-Gui Peng, Ai-Hua Sun, Ping Wang, Zhi Yang, Xi Zhang, Cheng Qian |
Journal | Journal of immunotherapy (Hagerstown, Md. : 1997)
(J Immunother)
2018 Jul/Aug
Vol. 41
Issue 6
Pg. 306-311
ISSN: 1537-4513 [Electronic] United States |
PMID | 29864079
(Publication Type: Case Reports, Journal Article, Review)
|
Chemical References |
|
Topics |
- Antigens, CD19
(metabolism)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cell Proliferation
- Child
- Drug Resistance, Neoplasm
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunotherapy, Adoptive
(methods)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(immunology, therapy)
- Remission Induction
- T-Lymphocytes
(physiology, transplantation)
- Transplantation Conditioning
- Transplantation, Haploidentical
- Treatment Outcome
|